banner image

老人癡呆症 / 腦退化症
Dementia

There are currently over 100 different forms of dementia and according to the UK Alzheimer"s Society: Dementia currently affects over 750,000 people in the UK. Approximately 18,000 people with dementia are under the age of 65. Dementia affects one person in 20 over the age of 65 and one person in five over the age of 80. The number of people with dementia is steadily increasing. Alzheimer"s disease is the most common form of dementia, making up 55 per cent of all cases of dementia. There are nearly 18 million people with dementia in the world.

Recently clinical trials have been carried out which investigated the possibility of treating dementia with fatty acids. One focussed on Huntington"s Chorea, the other on Alzheimer"s Disease. Both had positive results indicating that some forms of dementia can be treated with fatty acid supplementation, specifically with the omega-3 fatty acid, EPA and the omega-6 fatty acid, GLA.

Omega product contains a unique ratio of ultra-pure EPA from marine fish oil and cold-pressed virgin evening primrose oil (which is rich in GLA).

Definition of Dementia
The term dementia describes an array of brain disorders that share the symptom of loss of brain function, which is usually progressive and ultimately severe. One of the most well known forms of dementia is Alzheimer"s disease but there are currently over 100 different forms of it.

As more research is being done into this disease, scientists are discovering that supplementation with certain fatty acids may slow the degeneration of brain tissue and in some cases even improve motor function.

How Fatty Acids Help Dementia
Fatty acids help to form the phospholipids in the brain, which are vital for cell signalling. Cell signalling is important for brain function, the degeneration of which is the primary symptom of dementia.

Without enough fatty acids, communication between our cells ceases to operate properly and this can have an adverse effect on brain function. Conversely, with fatty acid supplementation, cell signalling has been shown to improve.

The Volumetric Niacin Response (VNR) is a special test that measures cell signalling and brain function. In 2005 Professor Puri carried out a trial on a small number of patients with advanced Alzheimer"s disease. He measured their VNR at the beginning of the six-month trial and again at the end of it. In the intervening time, half the patients were given omega product and the other half were given a placebo (a dummy supplement with no medicinal properties). The trial was double-blind so neither the patients nor Professor Puri knew who was being given omega product and who was being given the placebo.

The key findings were as follows: cell signalling continued to deteriorate in those Alzheimer"s patients who were taking the placebo. Over the same period, however, those patients taking omega product actually showed an improvement in their volumetric niacin response and therefore improved cell signalling in the body and brain.

Professor Puri, Professor Vaddadi, and colleagues also carried out trials into the effects of fatty acid supplementation on patients with Huntington"s chorea. Again improvements were seen in terms of the amount of brain tissue present as well as motor function after supplementation wtih fatty acids compared with the placebo.